Cyclomenol is a bactericide compound, discovered at Institute Francais Du Petrole.

Litomeglovir is an antiviral agent.

Becanthone is an antischistosomal agent possesses the ability to inhibit tumors.

Xenygloxal was studied as an antiviral agent that has never been marketed.

Dribendazole is tiabendazole derivative. It was used as an anthelminthic agent.

Cicloxolone is a broad spectrum antiviral agent with a largely non-specific and complex mode of antiviral action. The drug was active during all stages of the virus replication cycle, indicating that it does not operate by the specific inhibition of any single essential virus gene product. The drug reduced the number of vesicular stomatitis virusparticles assembled and released by 100- to 1000-fold. Infectious virus yield was reduced 1000- to 10000-fold, giving a 10-fold or greater increase in the particle/p.f.u. ratio. The reduced number of virus particles produced in the presence of Cicloxolone results from two superimposed effects: suppression of vesicular stomatitis virussecondary transcription and viral protein synthesis, and perturbation of virion assembly.

Trovirdine [LY 300046, LY 300082, PETT 1] is a NNRT inhibitor of HIV-1 RT, which progressed through Phase II trials for the treatment of HIV infection. Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM. Cell culture experiments demonstrated that LY300046 was a potent inhibitor of the replication of HIV-1 in human T-cell lines and human PBL, including spread of the virus from infected to uninfected T cells. It was potent against patient isolates as well as laboratory isolates of HIV-1 but was not active against HIV-2 or simian immunodeficiency virus.

Fosarilate was studied as an antiviral agent. Information about the current use of this compound is not available.

Ftormetazine was studied as a psychotropic and an antiarrhythmic agent. Information about the current use of this compound is not available.

Panidazole, an antiprotozoal agent that was studied in patients for the treatment of intestinal amoebiasis and vaginal trichomoniasis. However, information about the further development of this drug is not available.